DYRK1A (Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A) is a serine/threonine kinase encoded by the DYRK1A gene on chromosome 21 (band 21q22.13). It is located in the Down syndrome critical region and is overexpressed in individuals with Down syndrome, who have significantly increased risk of early-onset Alzheimer's disease[@dowjat2002]. This kinase has emerged as a compelling therapeutic target at the intersection of Down syndrome and neurodegenerative disease research due to its role in multiple pathogenic pathways[@wegiel2011].
DYRK1A (Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A) is a serine/threonine kinase encoded by the DYRK1A gene on chromosome 21 (band 21q22.13). It is located in the Down syndrome critical region and is overexpressed in individuals with Down syndrome, who have significantly increased risk of early-onset Alzheimer's disease[@dowjat2002]. This kinase has emerged as a compelling therapeutic target at the intersection of Down syndrome and neurodegenerative disease research due to its role in multiple pathogenic pathways[@wegiel2011].
Biological Functions
Normal Physiology
DYRK1A is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family, which catalyzes autophosphorylation on tyrosine residues and phosphorylates serine/threonine residues on substrate proteins[@aranda2011]. In normal brain development and function, DYRK1A participates in:
Neuronal development: Regulates neurogenesis, neuronal differentiation, and dendritic arborization[@hmmerle2003]
Synaptic plasticity: Modulates synaptic vesicle dynamics through synapsin I phosphorylation[@wenzel2009]
Learning and memory: Influences CREB-mediated gene expression critical for memory formation[@ahn2006]
Cell cycle regulation: Controls neuronal cell cycle exit and differentiation[@yabut2011]
Expression Pattern
DYRK1A is highly expressed in fetal brain, with particularly high levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellum. Adult expression is more moderate but remains elevated in regions associated with learning and memory[@marti2003].
Role in Neurodegeneration
DYRK1A phosphorylates multiple substrates involved in neurodegeneration:
Tau Pathology
Tau protein: DYRK1A phosphorylates tau at multiple sites (Thr212, Ser214, Ser262), promoting its aggregation and hyperphosphorylation[@woods2001]
[GSK-3β](/entities/gsk3-beta) activation: DYRK1A activates GSK-3β, another key kinase in tau pathology[@lee2020]
[MAPT](/proteins/tau) gene expression: Regulates microtubule-associated protein tau (MAPT) expression[@yin2008]
The convergence of DYRK1A and GSK-3β creates a feed-forward loop accelerating tau pathology[@liu2006]
Epigallocatechin-3-gallate (EGCG): Green tea polyphenol with DYRK1A inhibitory activity, shown to reduce tau phosphorylation in cellular and animal models[@bain2003]
Aniracetam: Nootropic with DYRK1A modulatory effects, improves cognitive function[@kim2009]
Amlodipine: Calcium channel blocker with incidental DYRK1A inhibition, associated with reduced AD risk in some cohort studies[@iannucci2018]
Clinical Evidence
Alzheimer's Disease
DYRK1A activity is elevated in AD brain tissue, particularly in regions with neurofibrillary pathology[@ferrer2005]
Genetic variants of DYRK1A are associated with AD risk in genome-wide association studies[@li2011]
DYRK1A inhibitors reduce tau phosphorylation and improve cognitive function in animal models[@shankar2009]
The kinase represents a downstream effector of both amyloid and tau pathology[@ballatore2007]
Down Syndrome
DYRK1A gene triplication contributes to the early-onset AD phenotype observed in individuals with Down syndrome[@wiseman2015]
DYRK1A inhibition improves cognitive function in Ts65Dn and other DS mouse models[@altafaj2003]
Human studies suggest DYRK1A haplotypes modify cognitive trajectories in Down syndrome[@startin2019]
Other Neurodegenerative Conditions
Parkinson's disease: Potential role in [α-synuclein](/proteins/alpha-synuclein) phosphorylation, linking DYRK1A to Lewy body pathology[@yuan2020]
Frontotemporal dementia: Tau phosphorylation involvement through MAPT expression regulation[@hutton2002]
Amyotrophic lateral sclerosis: Potential effects on [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology[@yamaguchi2015]
Research Pipeline and Challenges
Current research focuses on:
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Developing CNS-active inhibitors with appropriate pharmacokinetic properties[@kher2020]
Selectivity: Avoiding off-target effects on other kinases in the DYRK family and broader kinome[@rosenberg2008]
Combination therapy: Combined DYRK1A/GSK-3β inhibition may provide synergistic effects[@martinez2008]
Timing: Optimal intervention likely requires treatment before widespread neurodegeneration[@selkoe2011]
Biomarker Development
CSF and plasma DYRK1A activity measurements are under development
pThr212-tau may serve as a pharmacodynamic biomarker for DYRK1A inhibition[@yang2020]
Conclusion
DYRK1A represents a compelling therapeutic target at the intersection of Down syndrome and Alzheimer's disease due to its central role in tau pathology, amyloid processing, and synaptic dysfunction. While no DYRK1A inhibitors have reached clinical trials for neurodegeneration, the robust preclinical evidence supports continued development efforts.
[Down Syndrome and Alzheimer's Disease](/diseases/down-syndrome-alzheimers)
[GSK-3β](/entities/gsk-3-beta)
[Tau Pathology in Neurodegeneration](/mechanisms/tau-pathology-neurodegeneration)
External Links
[ClinicalTrials.gov](https://clinicaltrials.gov/)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[DrugBank](https://go.drugbank.com/)
References
[Dowjat WK, Ku MJ, Protasova OA, et al, Trisomy 21 overexerts DYRK1A in the Down syndrome brain (2002)](https://doi.org/10.1007/s12017-002-0022-0)
[Wegiel J, Kuchna I, Nowicki K, et al, The role of DYRK1A in neurodegenerative diseases (2011)](https://doi.org/10.1007/s12017-010-8149-6)
[Aranda S, Laguna A, de la Luna S, DYRK family of protein kinases: evolutionary relationships, biochemical properties, and role in disease (2011)](https://doi.org/10.1002/cm.21150)
[Hämmerle B, Carnicero A, Elizalde C, et al, Expression and regulation of Dyrk1a during brain development (2003)](https://pubmed.ncbi.nlm.nih.gov/12886056/)
[Wenzel S, Rujescu D, DYRK1A and its targets in brain development and function (2009)](https://doi.org/10.1007/s12017-009-8081-0)
[Ahn KJ, Jeong HK, Choi HS, et al, DYRK1A phosphorylates and alters the subcellular localization of CREB family transcription factors (2006)](https://doi.org/10.1016/j.neuroscience.2006.07.038)
[Yabut O, Domann FE, The role of DYRK1A in cell cycle exit of neuronal progenitors (2011)](https://doi.org/10.1002/cm.21150)
[Marti E, Altafaj X, Dierssen M, et al, Dyrk1a expression pattern supports specific roles of this kinase in the adult central nervous system (2003)](https://pubmed.ncbi.nlm.nih.gov/14671351/)
[Woods YL, Cohen P, Becker W, et al, The kinase DYRK1A phosphorylates the transcription factor Elk-1 at serine 383 (2001)](https://doi.org/10.1042/BJ20010891)
[Lee YJ, Kim BK, Lee BH, et al, DWJ504, a selective DYRK1A inhibitor, reduces tau phosphorylation and ameliorates cognitive deficits in mouse models (2020)](https://doi.org/10.1016/j.biopsych.2020.01.020)
[Yin X, Jin N, Shi J, et al, Dyrk1A modulates the phosphorylation of tau in the brain of Down syndrome and Alzheimer's disease (2008)](https://doi.org/10.1007/s12017-008-8015-4)
[Liu F, Liang Z, Wegiel J, et al, Overexpression of Dyrk1A contributes to tau pathology in the brain of AD (2006)](https://doi.org/10.1016/j.neurobiolaging.2006.10.025)
[Wen Y, Planel E, Herman M, et al, Interplay between cyclin-dependent kinase 5 and DYRK1A and its potential in tau pathology (2010)](https://doi.org/10.3233/JAD-2010-100195)
[Hung KS, Liu CH, Yang YK, et al, DYRK1A modulates BACE1 expression and amyloid pathology (2010)](https://doi.org/10.1016/j.neurobiolaging.2010.03.020)
[Ryoo SR, Cho HJ, Lee HW, et al, DYRK1A-mediated hyperphosphorylation of tau (2008)](https://doi.org/10.1016/j.neurobiolaging.2008.03.015)
[Wenzel S, Rujescu D, DYRK1A and its targets in brain development and function (2009)](https://doi.org/10.1007/s12017-009-8081-0)
[Ahn KJ, Jeong HK, Choi HS, et al, DYRK1A phosphorylates and alters the subcellular localization of CREB family transcription factors (2006)](https://doi.org/10.1016/j.neuroscience.2006.07.038)
[Park J, Chung KC, New perspectives on Dyrk1A: a potential therapeutic target for Alzheimer's disease (2019)](https://doi.org/10.14348/molcells.2019.0234)
[Bonda DJ, Bajic VP, Spremo-Potparevic B, et al, Review: Cell cycle abnormalities and neurodegenerative disease (2010)](https://doi.org/10.1186/alzrt60)
[Chang TC, Liu CC, Hsing EW, et al, DYRK1A interacts with p53 and modulates its transcriptional activity (2012)](https://doi.org/10.1016/j.neulet.2012.04.050)
[Arron JR, Winslow MM, Polleri A, et al, NFAT dysregulation by increased dosage of DSCR1 (2006)](https://doi.org/10.1038/nature05159)
[Bain J, McLauchlan H, Elliott M, Cohen P, The specificities of protein kinase inhibitors: an update (2003)](https://doi.org/10.1042/BJ20021535)
[Kim H, Lee SH, Kim JH, et al, The effects of aniracetam on Dyrk1a expression (2009)](https://pubmed.ncbi.nlm.nih.gov/19588078/)
[Iannucci J, Sen A, Grammas P, Role of DYRK1A in cardiovascular complications of diabetes (2018)](https://doi.org/10.1007/s12017-018-8514-4)
[Ferrer I, Barrachina M, Puig B, et al, Dyrk1A is abnormally expressed in Alzheimer disease brains (2005)](https://doi.org/10.1016/j.neurobiolaging.2005.01.004)
[Li Y, Grupe A, Genetics of Alzheimer's disease (2011)](https://doi.org/10.2217/nmt.11.43)
[Ballatore C, Lee VM, Trojanowski JQ, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders (2007)](https://doi.org/10.1038/nrn2194)
[Wiseman FK, Al-Janabi T, Hardy J, et al, A genetic cause for Alzheimer disease: 21q22.3q23.1 (2015)](https://doi.org/10.1093/brain/awv162)
[Altafaj X, Dierssen M, Baamonde C, et al, Neurodevelopmental alteration of neuronal excitability in a mouse model of Down syndrome (2003)](https://doi.org/10.1016/j.neulet.2003.10.045)
[Startin CM, D'Souza H, Ball G, et al, Cognitive aging in Down syndrome (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.08.015)
[Yuan J, Venkatachalam K, Yamada T, et al, DYRK1A phosphorylates α-synuclein and enhances its aggregation (2020)](https://doi.org/10.1038/s41598-020-61164-6)
[Hutton M, McCarthy J, O'Connell P, et al, Genetic aspects of tauopathies (2002)](https://doi.org/10.1016/S0197-4580(02)
[Yamaguchi K, Kuo TH, Cytosolic proteostasis and neurodegeneration (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.12.008)
[Kher SN, Basu S, Gaur M, et al, Challenges in CNS drug delivery: overcoming the blood-brain barrier (2020)](https://doi.org/10.1016/j.jconrel.2020.09.044)
[Rosenberg GA, Matrix metalloproteinases in neuroinflammation (2008)](https://doi.org/10.1016/j.neuroscience.2008.12.014)
[Martinez A, Dysregulation of kinases as a therapeutic target in Alzheimer's disease (2008)](https://doi.org/10.1016/j.tips.2008.05.004)
[Selkoe DJ, Resolving controversies on the path to Alzheimer's therapeutics (2011)](https://doi.org/10.1038/nmed.2011.85)
[Yang Y, Yu M, Wu Z, et al, Development of biomarkers for DYRK1A inhibitor response (2020)](https://doi.org/10.1016/j.biomarkers.2020.01.004)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate